Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors

Conclusions Volasertib had a manageable safety profile up to the MTD determined as 300 mg. Exposure to volasertib and its metabolite increased with increasing doses. The safety profile of volasertib in Japanese patients is comparable with those previously obtained in Caucasian patients. These data support enrollment of Japanese patients in global clinical trials without dose modification.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

ConclusionsPamiparib combined with ld TMZ continues to demonstrate promising antitumor activity and remains generally well tolerated in pts with advanced solid tumors.Clinical trial identificationNCT03150810.Editorial acknowledgementIra Mills, PhD, and Shannon Davis at Ashfield Healthcare Communications, Middletown, CT.Legal entity responsible for the studyBeiGene USA, Inc.FundingBeiGene USA, Inc.DisclosureA. Stradella: Honoraria (self): Roche; Honoraria (self): Celgene; Honoraria (self): Pfizer. M.L. Johnson: Research grant / Funding (institution): BerGenBio; Research grant / Funding (institution): Lilly; Research grant /...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Perioperative CapeOx showed good feasibility and favorable efficacy with sufficient pathological response, although statistical significance at .058 did not reach the commonly accepted cutoff of .05. The data obtained using this novel approach warrant further investigations. PMID: 31570518 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
ConclusionsAprutumab ixadotin was poorly tolerated, with an MTD found to be below the therapeutic threshold estimated preclinically; therefore, the trial was terminated IdentifierNCT02368951.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: The present study determined the dose for further clinical trials of IP PTX to be 20 mg/m2, when combined with the 5-weekly SP regimen. PMID: 31487733 [PubMed - as supplied by publisher]
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
Publication date: Available online 31 August 2019Source: International Journal of Surgery Case ReportsAuthor(s): Yuki Kaneko, Shin Saito, Daijiro Takahashi, Takashi Ui, Hidenori Haruta, Kentaro Kurashina, Hironori Yamaguchi, Yoshinori Hosoya, Joji Kitayama, Alan Kawarai Lefor, Naohiro SataAbstractIntroductionImmune thrombocytopenic purpura is an acquired thrombocytopenia. Preoperative management of thrombocytopenia is important in patients with gastric cancer. Partial splenic embolization can be effective for patients with thrombocytopenia, but could lead to ischemic necrosis of the remnant stomach when performing subtotal...
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
Conclusion.This S‐1 and PTX cotherapy dose and schedule showed satisfactory efficacy, with mild toxicities, in patients with previously treated advanced NSCLC.
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer, Chinese Edition, Clinical Trial Results Source Type: research
Authors: Sasaki K, Zhou Q, Matsumoto Y, Saiki T, Moriyama M, Saijo Y Abstract Two patients underwent hemodialysis. Case 1 with stage IV gastric cancer was treated with reduced doses of capecitabine (1,000 mg/m2/day, days 1 to 14) and oxaliplatin (65 mg/m2, day 1). Although grade 1 thrombocytopenia occurred in the first cycle, grade 3 thrombocytopenia developed in the second cycle because of increasing dosage. After the dosage was reduced, chemotherapy was continued safely. Case 2 with stage IA gastroesophageal cancer was treated with radiotherapy followed by chemotherapy. Treatment with the same dose of CapeOX ther...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Conclusions: Oxaliplatin-based regimen is superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced GC, and is associated with less toxicity and better tolerability.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Authors: Sikiric P, Hahm KB, Blagaic AB, Tvrdeic A, Pavlov KH, Petrovic A, Kokot A, Gojkovic S, Krezic I, Drmic D, Rucman R, Seiwerth S Abstract We reviewed again the significance of the stable gastric pentadecapeptide BPC 157 as a likely mediator of Robert's stomach cytoprotection/adaptive cytoprotection and organoprotection and as novel mediator of Selye's stress coping response to reestablish homeostasis. Specific points of BPC 157 therapy and the original concept of Robert's cytoprotection/adaptive cytoprotection/organoprotection are discussed, including the beneficial effects of BPC 157. First, BPC 157 protect...
Source: Gut and Liver - Category: Gastroenterology Tags: Gut Liver Source Type: research
Publication date: Available online 10 May 2019Source: Surgery (Oxford)Author(s): Vishy MahadevanAbstractThe pancreas is a large, retroperitoneal organ situated immediately behind the posterior wall of the lesser sac, in the floor of the supracolic compartment of the abdominal cavity. Although principally an exocrine gland, the pancreas also performs crucially important endocrine functions. The exocrine pancreas secretes digestive enzymes. These are produced by the pancreatic acini and released into an elaborate ductal system which eventually opens into the second part of the duodenum. The endocrine component of the pancrea...
Source: Surgery (Oxford) - Category: Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Gastric (Stomach) Cancer | Gastroenterology | Hematology | Investigational New Drugs | Thrombocytopenia | Toxicology